Across TCGA pan-cancer cohorts, EI24P4 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of EI24P4’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where EI24P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EI24P4 is over-expressed in tumor.
PRAD are the cancer types where EI24P4 tumor–normal differential expression is most reproducible.